Private Banking
|
Professional Solutions
|
Investment Management
|
Investment Banking
|
About us
EN
Contact
Login
Van Lanschot Kempen Logo
Solutions
Sectors
Careers
Van Lanschot Kempen Logo
Login
Home
Investment Banking
Corporate Finance
Transactions
2013
Cardio3 July
Jul 2013
Sole Global Coordinator & Joint Bookrunner
€ 26.4 million
Initial Public Offering
Cardio3
Cardio3 BioSciences is a Belgian biotechnology company aiming to heal heart failure
Cardio3 BioSciences floated on Euronext Brussels and Euronext Paris
Proceeds of the IPO were dedicated to fund European phase III trials of its flagship product, C-Cure
Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner